Cardion - instructions for use, dose, side effects, contraindications

Description:Hard gelatin capsules No. 1 in white. The contents of the capsules are a white or almost white crystalline powder with a weak odor. The powder is hygroscopic, it is allowed to clump.

Pharmacotherapeutic group:Metabolic means

ATX: & nbsp

C.01.E.B.22 Meldoney

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Synthetic analogue of gamma-butyrobetaine, inhibits gamma-butyrobetaine hydroxylase, reduces the synthesis of carnitine and transport of long chain fatty acids through cell membranes, prevents the accumulation of activated forms of unoxidized fatty acids - acylcarnitine and acylcoenzyme A - in cells. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine is intensively synthesized, vasodilatory properties. Under conditions of ischemia meldoon restores the equilibrium of the processes of oxygen delivery and its consumption in cells, prevents the violation of the transport of adenosine triphosphate (ATP); simultaneously, it activates glycolysis, which proceeds without additional consumption of oxygen.

The mechanism of action determines the variety of pharmacological effects of meldonia: increase of working capacity, reduction of symptoms of mental and physical overstrain, activation of immunity, cardioprotective action. In the case of acute ischemic damage, the myocardium slows the formation of the necrotic zone, shortens the rehabilitation period. With heart failure increases myocardial contractility, increases tolerance to physical exertion; reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes redistribution of blood in favor of the ischemic site.

Characteristic tonic effect on the central nervous system, elimination, functional disorders of the vegetative nervous system in the syndrome abstinence in patients with chronic alcoholism.

Pharmacokinetics:

After oral intake quickly absorbed from the gastrointestinal tract, bioavailability is 78%. The maximum concentration in the blood plasma is achieved after 1-2 hours. Metabolized in the body with the formation of two major metabolites, which are excreted by the kidneys. The half-life period depends on the dose and is 3-6 hours.

Indications:

Reduced efficiency; mental and physical (including athletes) overload.

In the complex therapy: coronary heart disease (angina pectoris), chronic heart failure, cardialgia against the background of dyshormonal myocardial dystrophy.

As part of complex therapy: cerebrovascular accident (ischemic stroke, chronic cerebrovascular insufficiency).

An abstinent condition with chronic alcoholism (as part of an integrated specific therapy).

Contraindications:Hypersensitivity to the main and / or auxiliary components of the drug; increased intracranial pressure (with violation of venous outflow and intracranial tumors); pregnancy; the period of breastfeeding; age to 18 years (efficacy and safety not established).

Carefully:

Chronic liver and / or kidney disease (due to lack of data).

Pregnancy and lactation:

Safety of use during pregnancy is not proven. To avoid possible adverse effects on the fetus, during pregnancy the drug is not appoint.

It is not known whether meldoon with breast milk. If necessary use of the drug Cardionate ®, during lactation should stop breastfeeding.

Dosing and Administration:

Inside. Capsules should be swallowed whole, washed down with water.

In view of the possible development of an exciting effect, the drug is recommended for use in the first half of the day.

Reduced performance, mental and physical overload - 500 mg (2 capsules) 2 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks.

Athletes - 500 mg of 1.0 g (2 - 4 capsules) 2 times a day before training. The duration of the course in the preparatory period of training is 14-21 days, during the competition -10-14 days.

Ischemic heart disease (angina pectoris), chronic heart failure - 500 mg - 1.0 g (2 - 4 capsules) per day, applying the entire dose at once or dividing it into 2 divided doses. The course of treatment is 4-6 weeks.

Cardialgia with dyshormonal myocardiodystrophy - 250 mg twice a day.The course of treatment is 12 days.

Violation of cerebral circulation. With ischemic stroke - after the end of a 10-day course of therapy with the injection form of the Cardionate® patient transfer to the preparation in capsules of 500 mg - 1.0 g (2 - 4 capsules) per day, taking the entire dose at once or dividing it into 2 divided doses. The general course of treatment is 4-6 weeks.

For chronic cerebrovascular insufficiency, 500 mg (2 capsules) per day. The course of treatment is 2-3 weeks. The need for repeated courses of treatment (2-3 times a year) is determined by the doctor.

An abstinence condition in chronic alcoholism - 500 mg (2 capsules) 4 times a day. The course of treatment is 7-10 days.

Side effects:

From the cardiovascular system: tachycardia, decreased or increased blood pressure.

From the gastrointestinal tract: dyspeptic phenomena.

From the central nervous system: excitation.

Allergic reactions: redness and itching of the skin, rash, swelling.

Other: eosinophilia, general weakness.

Overdose:

Symptoms: decrease in blood pressure, accompanied by a headache, tachycardia, dizziness, general weakness.

Treatment symptomatic.

Interaction:

You can combine with antianginal drugs, anticoagulants, antiaggregants, antiarrhythmic drugs, diuretics, bronchodilators. Strengthens the coronarodilating, some antihypertensive drugs, cardiac glycosides. When combined with nitroglycerin, nifedipine, alpha-adrenoblockers, other antihypertensive drugs and peripheral vasodilators, care should be taken in view of the possible development of moderate tachycardia and arterial hypotension.

Special instructions:

Care should be taken when treating patients with chronic liver and kidney diseases, especially with prolonged use of the drug.

Insufficient data on use in children.

Effect on the ability to drive transp. cf. and fur:There is no evidence of the adverse effect of Cardionate® on the ability to drive vehicles and mechanisms.

Form release / dosage:Capsules of 250 mg.

Packaging:

10 capsules per contour cell packaging made of polyvinylchloride film and aluminum foil.

2, 4 or 10 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In a dry place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

4 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-000612

Date of registration:21.06.2010 / 05.10.2017

Expiration Date:Unlimited

The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia

Manufacturer: & nbsp

HEMOFARM, LLC Russia

Representation: & nbspNizhpharm, JSCNizhpharm, JSCRussia

Information update date: & nbsp12.12.2017

Illustrated instructions

Instructions

Cardionate® (Cardionate)